Free Trial

Acumen Pharmaceuticals Q4 2024 Earnings Report

Acumen Pharmaceuticals logo
$0.98 -0.01 (-1.02%)
As of 04/4/2025 04:00 PM Eastern

Acumen Pharmaceuticals EPS Results

Actual EPS
-$0.62
Consensus EPS
-$0.47
Beat/Miss
Missed by -$0.15
One Year Ago EPS
N/A

Acumen Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Acumen Pharmaceuticals Announcement Details

Quarter
Q4 2024
Time
Before Market Opens

Conference Call Resources

Remove Ads

Acumen Pharmaceuticals Earnings Headlines

Acumen presented results from pTau217 assay in Phase 2 ALTITUDE-AD trial
Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
Equities Analysts Set Expectations for ABOS FY2029 Earnings
See More Acumen Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Acumen Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Acumen Pharmaceuticals and other key companies, straight to your email.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals (NASDAQ:ABOS), a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

View Acumen Pharmaceuticals Profile

More Earnings Resources from MarketBeat